1. Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor—Acute Myeloid Leukemia: Systematic Review and Meta-Analysis
   Shyam Srinivasan et al, 2022, Clinical Lymphoma Myeloma and Leukemia CrossRef
2. Therapy-Related Core Binding Factor Acute Myeloid Leukemia
   Binsah George et al, 2023, International Journal of Hematologic Oncology CrossRef
3. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
   Tamara Castaño-Bonilla et al, 2021, Scientific Reports CrossRef
4. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications
   Chinmayee Panigrahi et al, 2023, BMJ Case Reports CrossRef
5. Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes
   Feng Xu et al, 2022, Journal of Cellular and Molecular Medicine CrossRef
6. Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1- RUNX1T1 or CBFB-MYH11 fusions
   Wei Qin et al, 2022, Turkish Journal of Hematology CrossRef
7. Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia
   Gabriele Lo Iudice et al, 2022, Journal of Translational Medicine CrossRef
8. A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment
   Serena Tseng et al, 2023, Pharmaceuticals CrossRef